Literature DB >> 6985248

Antigenic variation in cancer metastasis: immune escape versus immune control.

V Schirrmacher, M Fogel, E Russmann, K Bosslet, P Altevogt, L Beck.   

Abstract

Antigenic variation in cancer metastasis was observed in a syngeneic murine tumor system consisting of a low metastatic parental tumor line (derived from a methylcholanthrene-induced DBA/2 T lymphoma, Eb), a high metastatic spontaneous variant thereof (ESb), and a low metastatic 'revertant' from ESb (ESb-M). All three lines expressed tumor-associated transplantation antigens (TATA) which elicited specific T cell-mediated antitumor immune reactions in the host. The strongest host response was elicited upon intradermal inoculation. It could be followed by (a) the infiltration of the locally growing tumor by host cells, such as lymphocytes and macrophages, (b) the establishment of specific systemic antitumor immunity, (c) the generation of immune cells capable of transferring protective antitumor immunity into a normal syngeneic recipient, and (d) the generation of tumor specific cytotoxic T lymphocytes (CTL). Anti-TATA CTL were used as typing reagents to investigate the stability or variability in the TATA expression by cloned tumor cell lines. Antigenic variability in the TATA expression was seen under various conditions: (a) clone-dependent variation in the sensitivity to anti-TATA CTL lysis upon prolonged growth in tissue culture, (b) qualitative change in the TATA (TATA1 leads to TATA2) upon successive i.p. transplantation of the parental Eb tumor line and, (c) generation of TATA negative immune escape variants (TATA2 leads to TATA-) during metastasis formation from a s.c. site. The relative inefficiency of specific immunization procedures against ESb was found to be due to the effective generation of TATA negative variants by this highly metastatic tumor. The balance between immune control and immune escape could be influenced to the advantage of the host by some means, for instance optimizing the route of antitumor-immune sensitization or by infusion of allogeneic but H-2 identical antitumor-immune T cells. Such immune cells recognized the tumor via minor histocompatibility antigens and thus circumvented the need of TATA recognition. Finally, manipulations at the cell surface of the highly malignant ESb tumor such as those introduced in the ESb-M variant were found to dramatically effect its metastatic potential.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6985248     DOI: 10.1007/BF00046830

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  104 in total

Review 1.  Virus augmentation of the antigenicity of tumor cell extracts.

Authors:  F C Austin; C W Boone
Journal:  Adv Cancer Res       Date:  1979       Impact factor: 6.242

2.  Gene duplication and transposition linked to antigenic variation in Trypanosoma brucei.

Authors:  E Pays; N Van Meirvenne; D Le Ray; M Steinert
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

3.  Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells.

Authors:  J R Berenson; A B Einstein; A Fefer
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

4.  Generation of cytotoxic lymphocytes to syngeneic tumor by using co-stimulator (Interleukin 2).

Authors:  G B Mills; V Paetkau
Journal:  J Immunol       Date:  1980-11       Impact factor: 5.422

5.  Specific cytotoxic lymphocytes against syngeneic tumors are generated in culture in the presence of syngeneic, but not xenogeneic, serum.

Authors:  M Fogel; S Segal; E Gorelik; M Feldman
Journal:  Int J Cancer       Date:  1978-09-15       Impact factor: 7.396

6.  Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro.

Authors:  M A Cheever; P D Greenberg; A Fefer
Journal:  Cancer Res       Date:  1981-07       Impact factor: 12.701

7.  Immune-mediated arrest and reversal of established visceral metastases in athymic mice.

Authors:  R H Wiltrout; P Frost; M K Morrison; R S Kerbel
Journal:  Cancer Res       Date:  1979-10       Impact factor: 12.701

8.  The tumor dormant state. Comparison of L5178Y cells used to establish dormancy with those that emerge after its termination.

Authors:  K J Weinhold; D A Miller; E F Wheelock
Journal:  J Exp Med       Date:  1979-03-01       Impact factor: 14.307

9.  Hepatocyte-tumor cell interaction in vitro. I. Conditions for rosette formation and inhibition by anti-H-2 antibody.

Authors:  V Schirrmacher; R Cheingsong-Popov; H Arnheiter
Journal:  J Exp Med       Date:  1980-04-01       Impact factor: 14.307

10.  Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes.

Authors:  E Fernandez-Cruz; B A Woda; J D Feldman
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

View more
  28 in total

1.  In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: intra-pinna immunization followed by restimulation in the peritoneal cavity.

Authors:  V Schirrmacher; S Leidig; A Griesbach
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  The neural cell adhesion molecule N-CAM enhances L1-dependent cell-cell interactions.

Authors:  G Kadmon; A Kowitz; P Altevogt; M Schachner
Journal:  J Cell Biol       Date:  1990-01       Impact factor: 10.539

Review 3.  Rationale for immunotherapy of renal cell carcinoma.

Authors:  R Heicappell; R Ackermann
Journal:  Urol Res       Date:  1990

4.  The growth and metastasis of four commonly used tumour lines implanted into eight different sites: evidence for site and tumour effects.

Authors:  W S Chan; C M Page; J R Maclellan; G A Turner
Journal:  Clin Exp Metastasis       Date:  1988 May-Jun       Impact factor: 5.150

5.  Molecular identification of lectin binding sites differentiating related low and high metastatic murine lymphomas.

Authors:  E Lang; V Schirrmacher; P Altevogt
Journal:  Clin Exp Metastasis       Date:  1988 Jan-Feb       Impact factor: 5.150

Review 6.  Implications of tumor progression on clinical oncology.

Authors:  D R Welch; S P Tomasovic
Journal:  Clin Exp Metastasis       Date:  1985 Jul-Sep       Impact factor: 5.150

Review 7.  Somatic cell fusion as a source of genetic rearrangement leading to metastatic variants.

Authors:  L Larizza; V Schirrmacher
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

8.  Interaction of high or low metastatic related tumor lines with normal or lymphokine-activated syngeneic peritoneal macrophages: in vitro analysis of tumor cell binding and cytostasis.

Authors:  V Schirrmacher; B Appelhans
Journal:  Clin Exp Metastasis       Date:  1985 Jan-Mar       Impact factor: 5.150

Review 9.  Nonmetastatic tumor cells acquire metastatic properties following somatic hybridization with normal cells.

Authors:  P De Baetselier; E Roos; L Brys; L Remels; M Gobert; D Dekegel; S Segal; M Feldman
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

Review 10.  New insights into tumor-host interactions in lymphoma metastasis.

Authors:  V Umansky; V Schirrmacher; M Rocha
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.